source
- Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipelineCentered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
- Madrigal's Rezdiffra sales top forecasts as Gilead announces job cutsMadrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen. The outperformance highligh…